Perinatal Covid-19 Infection, NO Pathway, and Minipuberty

Inclusion criteria

• Group 1 : Newborn infants (24 to 41 weeks gestational age) or young infants (< 3 months) admitted at the maternity ward or at the Department of Neonatology at Jeanne de Flandre Hospital, CHU of Lille with perinatal COVID-19 infection defined by:

• Antenatal COVID-19 infection: pregnant women with positive PCR test at any time of the pregnancy;
• Post-natal COVID-19 infection: newborn or young infants (< 3 months) with positive PCR test in pharynx or stools as part of their treatment.
• Group 2 : Newborn infants (24 to 41 weeks gestational age) or young infants (< 3 months) admitted at the maternity ward or at the Department of Neonatology at Jeanne de Flandre Hospital, CHU of Lille for severe cardiorespiratory diseases requiring inhaled NO treatment.
• Group 3 : The control group without perinatal COVID-19 infection and no inhaled NO treatment will be matched to the two other groups on age at birth (± 2 weeks of gestation), on postnatal age (± 3 weeks), on respiratory failure (yes/no).
• No inclusion in another ante- or post-natal trial;
• Written consents from both parents.
• Social security affiliation

Exclusion criteria

• Preterm birth less than 24 weeks gestational age.
• Severe brain lesions: bilateral and extensive periventricular leukomalacia, intracranial hemorrhage grade 3 or 4;
• One or both of the parents is unable to read or understand French language, or refuse to participate